SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.1 Variant, Kappa)

COVID-19 Neutralizing Antibodies Detection Kit (B.1.617.1 Variant, Kappa); 2019-nCoV Neutralizing Antibodies Detection Kit (B.1.617.1 Variant, Kappa); 2019-nCoV Spike Protein S1 (RBD) Neutralizing Antibodies Detection Kit (B.1.617.1 Variant, Kappa)

Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many wild animals. Recently, a new severe acute respiratory syndrome beta-coronavirus called SARS-CoV-2 has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S1 subunit contains a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells.The SARS-CoV-2 Neutralizing Antibodies Detection Kit (B.1.617.1 Variant, Kappa) contains key reagents required to test the presence of functional neutralizing antibodies against SARS-CoV-2 (variant B.1.617.1) present in the serum or plasma or/and to test the cross-reaction of SARS-CoV-2 neutralizing antibodies directed to previous variants. It is an easy and fast alternative to the classical neutralization assay using Vero E6 cells. This Detection Kit is based on a colorimetric reaction, which measures the binding of the RBD of the Spike S protein from SARS-CoV-2 (variant Kappa) to its human receptor ACE2. The presence of neutralizing/blocking antibodies in the samples are detected by reduction of signal indicating the inhibition of the Spike-ACE2 binding. Three sublineages have been found, B.1.617.1 (variant Kappa) and B.1.617.3 containing 4 mutations in the Spike protein with a double mutations in the Receptor Binding Region (L452R, E484Q) and B.1.617.2 (variant Delta) that is different since it contains the mutation T478K instead of E484Q. These variants (especially the B.1.617.1 & B.1.617.2) of the SARS-CoV-2 coronavirus have evolved as fast-growing variants outpacing other variants.

To measure the presence of neutralizing/blocking antibodies in human serum/plasma that inhibit the binding of the SARS-CoV-2 Spike (RBD) (B.1.617.1 Variant, Kappa) protein to its human receptor ACE2.

+4°C

BLUE ICE

12 months after the day of manufacturing. See expiry date on ELISA Kit box.

瑞士

Plasma, Serum